GLP-1 Cost and Supply in the UK: The Full 12-Month Budget Guide

The capsule

GLP-1 weight management in the UK splits into three cost-paths, and the gap between the cheapest and most expensive route is substantial. The NHS route, governed by NICE TA1026 and rolled out across Integrated Care Boards from 2026, carries a prescription charge per item and a clinical pathway you do not pay for directly. The private clinic route, where a programme typically bundles the medication with coaching, nurse contact and dose titration, generally runs at around two hundred to four hundred pounds a month all-in. The pharmacy-direct route, where an online pharmacy dispenses against a prescriber consultation with little or no wraparound programme, generally runs at around one hundred and fifty to two hundred and fifty pounds a month. Over twelve months, this gives a realistic all-in budget range of around one thousand two hundred pounds to four thousand eight hundred pounds depending on the route, the medication and the dose you settle at. The rest of this guide walks through each path, the medications involved, the supply considerations, and the levers that move your total cost up or down.

The NHS path

The NHS route in England is shaped by NICE Technology Appraisal TA1026, which sets out the criteria under which a GLP-1 medication can be prescribed on the NHS for weight management. The headline criteria centre on body mass index thresholds, the presence of weight-related comorbidities, and a clinical assessment that less intensive interventions are not sufficient or have not been sufficient. NICE guidance is not a postcode lottery in principle, but the operational rollout is, because each of the forty-two English Integrated Care Boards is responsible for commissioning the local service that delivers the appraisal in practice.

This is the part of the system that most readers find confusing. NICE approving a medication for use on the NHS does not by itself mean the medication is available to you tomorrow at your GP. The ICB must commission a weight management service capable of meeting the NICE criteria, which usually means a tier three specialist weight management service, and then either accept referrals from primary care or stand up a pathway with sufficient capacity to absorb local demand. Capacity is the binding constraint. The medication itself is funded, but the consultation, monitoring and follow-up that NICE requires sit inside a service that has to be staffed and paid for.

As of mid-2026, the rollout across England is uneven. Some ICBs have a functioning pathway with reasonable waiting times. Some have a pathway with extended waiting times that effectively mean a two-figure number of months before you would see a prescriber. Some have a pathway in pilot form with limited geographic coverage. A handful have only recently begun commissioning work. Scotland, Wales and Northern Ireland operate under their own commissioning frameworks, with the Scottish Medicines Consortium and the All Wales Medicines Strategy Group fulfilling broadly similar roles to NICE for their respective nations.

We maintain a live view of where each English ICB sits in the rollout. If you want to know whether your local area has a working NHS pathway today, the ICB rollout tracker at /icb-rollout-tracker/ is the place to start. It summarises the status of each ICB, the eligibility criteria they are applying, and the realistic waiting time you should expect.

On cost, the NHS path is the cheapest of the three by a large margin. You pay the standard NHS prescription charge per item dispensed in England, unless you are exempt. Patients in Scotland, Wales and Northern Ireland do not pay a prescription charge. There are no consultation fees on top, because the consultation is part of the commissioned service. The trade-off is access. If your ICB has a six-month waiting list and you want to start in the next quarter, the NHS path is not a near-term option even if you are eligible.

The private clinic path

The private clinic path is the route most people end up on when they want to start within weeks rather than months and they want a programme around the medication rather than just the medication. A private clinic in this context typically means a specialist weight management provider, often digital-first, that offers a structured programme. The programme usually combines a GLP-1 medication with regular prescriber contact for dose titration, nurse or coach contact for adherence support, and some form of digital tracking or content delivered through an app or web portal.

The category includes operators such as Numan, Voy, Manual and Juniper. Each has a slightly different programme shape and pricing structure, and all of them are operating in a competitive UK market where pricing has been moving over the past year. We do not run a branded head-to-head comparison in this guide because pricing changes frequently and because the right choice depends on what you actually want from the programme. What we will say at a class level is that private clinic monthly cost in the UK in mid-2026 generally sits in a band of around two hundred to four hundred pounds, with the higher end of the band reflecting either a higher dose, a more involved programme, or a medication that carries a higher list price.

What you are paying for at a private clinic, beyond the medication itself, is the time of a prescriber willing to take clinical responsibility for your treatment, the dose titration plan, the safety review around starting dose and step-ups, and the wraparound programme. For a first-time GLP-1 user, the wraparound has real value, because the early weeks are where most side effects appear and most people who stop early do so. For an experienced user on a stable maintenance dose, the wraparound has less value, and the case for moving to a lower-touch pharmacy-direct route becomes stronger.

Private clinics generally bundle the medication into the monthly fee, so the headline price you see is closer to a true all-in number than at a pharmacy-direct provider, where you may see a low consultation fee and then a separate dispensing charge for the medication. Read the small print on whether the monthly fee includes the medication at all doses or only up to a certain dose, because some providers price the higher doses separately.

The pharmacy-direct path

The pharmacy-direct path is the lower-priced route and it has grown sharply in the UK over the past eighteen months. The category includes operators such as Phlo, Pharmacy2U, Simply Meds, Boots Online Doctor and Asda Online Doctor. Each of these is a registered UK pharmacy operating an online service, with a prescriber consultation built into the customer journey. You complete a clinical questionnaire, a prescriber reviews it, and if you are deemed suitable the medication is dispensed and shipped.

The pricing on the pharmacy-direct path generally sits in a band of around one hundred and fifty to two hundred and fifty pounds a month, with the lower end of the band reflecting either a starter dose or a competitive promotional price, and the upper end reflecting a higher maintenance dose. The gap between this band and the private clinic band, which is around fifty to one hundred and fifty pounds a month, is essentially the cost of the wraparound programme that the clinic provides and the pharmacy-direct route does not.

The pharmacy-direct route suits people who are confident managing their own treatment, who have either been on a GLP-1 medication before or who have a separate source of clinical guidance, and who want to keep the monthly cost as low as the legitimate market will allow. It is not a corner-cutting route in safety terms when used through a registered UK pharmacy with a real prescriber, because the prescriber retains clinical responsibility and will refuse to dispense if your answers indicate a contraindication. It is a corner-cutting route in service terms, because you are buying the medication and a prescription decision, not a programme.

Supply on the pharmacy-direct path has been the main source of friction in the UK over the past two years. Several of the named operators have at points been unable to fulfil orders for specific doses of specific medications, because manufacturer supply to UK wholesalers has tightened. The position has improved through 2026 but is not yet entirely stable. If you start on the pharmacy-direct path, expect occasional gaps where your preferred dose of your preferred medication is not in stock at your preferred pharmacy, and expect to have a fallback ready.

Medication-level cost differences

The three medication classes you are realistically choosing between for weight management in the UK are tirzepatide, semaglutide and liraglutide, marketed under the brand names Mounjaro, Wegovy, Ozempic and Saxenda. We will discuss them at a class level rather than running a branded comparison.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is the newer of the two main weight management options in widespread UK use and it carries a higher manufacturer list price per pen at higher maintenance doses. At pharmacy-direct prices it tends to sit at the upper end of the band described above. At private clinic prices it tends to push programmes toward the upper end of their band, particularly at maintenance doses.

Semaglutide is a GLP-1 receptor agonist. It is available as Wegovy, which is licensed in the UK specifically for weight management, and as Ozempic, which is licensed for type two diabetes and is sometimes prescribed off-label for weight where a clinician judges it appropriate. The off-label use of Ozempic for weight management has been a contested area in the UK, both because supply constraints have at points limited availability for the licensed diabetes indication and because the regulatory framing of off-label prescribing places more clinical responsibility on the prescriber. The cost of semaglutide-based weight management at retail is generally a step below tirzepatide-based weight management, although the gap varies by provider.

Liraglutide is the older GLP-1 receptor agonist, marketed as Saxenda for weight management. It is administered as a daily injection rather than a weekly one, and the clinical evidence base supporting it for weight management predates the newer medications. In the current UK market it is prescribed less often than it was three years ago, largely because the weekly-dose options have displaced the daily-dose option for most new patients. It can still be the right option in specific clinical circumstances, but on cost it does not generally undercut the newer options to a degree that would shift the decision on price alone.

Pricing at the manufacturer list level is published by Eli Lilly and Novo Nordisk, and is what feeds into the NHS reimbursement framework. Retail prices at private clinics and pharmacy-direct providers sit above the manufacturer list price by a margin that reflects dispensing, prescriber time, programme overhead and supply chain cost.

Twelve-month projected cost ranges

Translating the monthly bands into twelve-month projections is straightforward arithmetic, but the projection is only as good as the assumption that you stay on the same route and the same dose for the full twelve months. Many people do not. They start at a lower dose, step up over the first three to four months, and then settle at a maintenance dose for the remainder of the year. Some switch route partway through, typically from a private clinic to a pharmacy-direct provider once they are stable. Some pause for side effects and restart. Some stop altogether.

The pure-arithmetic projections are as follows. On the NHS path, your twelve-month medication cost is bounded by the prescription charges you pay over the year if you are not exempt, which works out at a low double-digit number of pounds for most patients. The wraparound clinical care is not paid for directly by you. On the pharmacy-direct path, at the lower band of around one hundred and fifty pounds a month, the twelve-month projection is around one thousand eight hundred pounds. At the upper band of around two hundred and fifty pounds a month, the twelve-month projection is around three thousand pounds. On the private clinic path, at the lower band of around two hundred pounds a month, the twelve-month projection is around two thousand four hundred pounds. At the upper band of around four hundred pounds a month, the twelve-month projection is around four thousand eight hundred pounds.

These are the all-in numbers, with the medication included. They do not include any out-of-pocket costs for tests, blood work or specialist consultations outside the programme, which most readers will not incur but some will, particularly if they have an underlying condition that warrants additional monitoring.

We maintain a separate calculator at /tools/12-month-supply-cost/ that lets you model the projection with your own assumptions about the dose you expect to settle at, the route you expect to take, and the number of months you expect to remain on treatment. The calculator is intended as a research and budgeting companion. It is not a clinical tool and it does not give clinical recommendations. The math is the math.

What changes the cost equation

Several variables move the twelve-month total up or down from the central projection, and it is worth being explicit about them before you commit to a budget.

Dose progression is the largest single variable on the up-side. Most GLP-1 medications start at a low dose and step up over the first few months. The starter dose is usually priced lower at retail than the maintenance dose, particularly at pharmacy-direct providers who price by dose strength rather than by month. If you settle at the highest available maintenance dose, your monthly cost in the second half of the year will be higher than your monthly cost in the first quarter, and your twelve-month total will land closer to the upper end of the band.

Side effects are the largest single variable on the down-side, but in a way that is not always welcome. A meaningful minority of GLP-1 users experience side effects severe enough to pause or stop treatment, particularly in the first six to eight weeks. If you stop, your twelve-month cost drops, but so do your weight management outcomes. The cost saving is not an outcome you should be optimising for.

Stopping versus continuing at the end of an initial period is a question most people on a GLP-1 medication face by month nine or ten. The evidence on weight regain after stopping is well established and unhelpful to anyone hoping the medication is a short-term intervention. Most people who stop regain a substantial fraction of the weight they lost within a year. Continuing the medication at a maintenance dose, sometimes at a lower dose than the peak, is the modal pattern. Build your budget around the assumption that you may want to continue beyond month twelve, not that you will definitely stop.

Switching route partway through the year is a lever many readers use to bring the total cost down. The typical pattern is to start on a private clinic path for the wraparound during the titration months, then move to a pharmacy-direct path for the maintenance months once you are stable. This works in practice, but it requires a clean handover, and it requires the pharmacy-direct provider to be willing to take you on at a maintenance dose without insisting you restart their own protocol. Most will, but some have minimum starter-dose protocols.

Switching medication partway through, typically from semaglutide to tirzepatide or vice versa, is a clinical decision rather than a cost decision, but it has cost consequences. The cost band at tirzepatide-based maintenance doses sits above the cost band at semaglutide-based maintenance doses, so switching up will move your monthly run-rate up.

Supply gaps, where your preferred medication at your preferred dose is unavailable at your preferred provider, force one of three responses. You wait, you switch dose, or you switch provider. Each has cost consequences. Waiting costs nothing in cash but costs adherence. Switching dose costs nothing if you step down but may cost outcomes. Switching provider often costs more because the new provider may have to run their own onboarding.

Affiliate disclosure

PeptideClear is an editorially independent UK publication. We earn a commission when readers click through to certain private clinics and pharmacies named in this guide and complete a purchase. This commission does not change the price you pay, and it does not change what we write. We do not accept payment for favourable coverage, we do not have a paid-placement model, and we do not allow commercial considerations to determine which providers we name or how we describe them. The bands and projections in this guide are derived from publicly observable retail pricing and manufacturer list prices, not from commercial relationships. Where a provider is named, it is named because it is a meaningful operator in the UK market at the time of writing, not because it pays us more.

Frequently asked questions

What is the cheapest legal route to a GLP-1 medication in the UK? The NHS route is cheapest if you are eligible under NICE TA1026 and your local ICB has a functioning pathway with an acceptable waiting time. If the NHS route is not realistically available to you in the timeframe you want, the pharmacy-direct route is the cheapest of the private options, generally at one hundred and fifty to two hundred and fifty pounds a month all-in.

How does the NHS path compare with the private path over twelve months? The NHS path costs you the prescription charge per item dispensed in England, or nothing in Scotland, Wales and Northern Ireland. The private path costs you the monthly programme fee multiplied by twelve, which lands somewhere between one thousand eight hundred pounds at the lower end of the pharmacy-direct band and four thousand eight hundred pounds at the upper end of the private clinic band. The cost gap is real and is the main reason readers ask us where their local ICB sits in the rollout.

When does the pharmacy-direct route beat the private clinic route? When you are stable on a maintenance dose, when you do not need the wraparound programme, and when you are confident managing your own treatment between prescriber contacts. The first three months of treatment are the period where the clinic wraparound has the highest value. Beyond that point, the case for switching down to pharmacy-direct strengthens.

Is Ozempic a cheaper route than Wegovy? Ozempic is licensed in the UK for type two diabetes, not for weight management. Where it is prescribed off-label for weight, the prescriber takes clinical responsibility for the off-label use. We do not recommend selecting a medication on cost grounds when the licensed and off-label routes are clinically distinct decisions. The retail cost of semaglutide for weight management in the UK is broadly comparable across the licensed and off-label routes, and the gap is not usually the determining factor.

What happens to my cost if I have to step up to a higher dose? Most providers price the higher maintenance doses above the starter doses, so your monthly cost rises through the titration period and lands at a higher steady-state than where you started. Build your twelve-month budget on the assumption that you settle at a maintenance dose, not on the assumption that you stay at the starter dose all year.

Should I budget for twelve months or longer? The evidence on weight regain after stopping a GLP-1 medication points toward continuing at a maintenance dose for many users beyond the initial twelve months. We suggest building your budget with a two-year view rather than a twelve-month view, and treating month twelve as a review point rather than an exit point. The calculator at /tools/12-month-supply-cost/ can be re-run with a twenty-four month horizon.

Sources

NICE Technology Appraisal TA1026 (semaglutide for weight management) and the associated NICE guidance for tirzepatide for weight management, accessed through the NICE website. NHS England commissioning guidance for tier three weight management services and the associated rollout documentation. Manufacturer published list prices for Mounjaro (Eli Lilly), Wegovy (Novo Nordisk), Ozempic (Novo Nordisk) and Saxenda (Novo Nordisk). NHS Business Services Authority prescription charge schedule. Scottish Medicines Consortium and All Wales Medicines Strategy Group decisions for the comparable nations. Publicly observable retail pricing at the named private clinics and pharmacy-direct providers as at May 2026.

This guide is editorial. It is not clinical advice and it does not recommend a dose, a medication or a provider for your individual circumstances. Decisions about whether to start, continue or stop a GLP-1 medication should be made with a prescriber who has reviewed your medical history.